The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell
Open accessAbstract
Glucocorticoids (GCs) are used to combat inflammatory diseases. Their beneficial effect relies mainly on the inhibition of NF-κB- and/or AP-1-driven proinflammatory gene expression. Previously, we have shown that GCs repress tumor necrosis factor-induced IL-6 gene expression by an NF-κB-dependent nuclear mechanism without changing the DNA-binding capacity of NF-κB or the expression levels of the cytoplasmic inhibitor of NF-κB (IκB-α). In the present work, we investigate the effect of GC repression on different natural and/or recombinant NF-κB-driven reporter gene constructs in the presence of increasing amounts of various coactivator molecules, such as CREB-binding protein (CBP), p300, and SRC-1. We found that GCs maintain their repressive capacities, irrespective of the amount of cofactor present in the cell. Similar results were obtained for the reciprocal transrepression of a GC receptor (GR) element-driven reporter gene by p65. We demonstrate that neither the expression levels of p65 and CBP nor their physical association are affected by activated GR. Using Gal4 chimeras, we show that repression by GCs is specific for p65-mediated transactivation, ruling out competition for limiting nuclear factors as the major underlying mechanism of gene repression. In addition, the transactivation potential of a point-mutated Gal4-p65 variant with a decreased CBP interaction capability is still repressed by GR. Finally, we present evidence that the specificity of GC repression on p65-driven gene expression is codetermined by the TATA box context.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses
Ghosh, S., May, M. J., & Kopp, E. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.225 · Cited by 5,182
Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., & Karin, M. (1995) · Science · doi:10.1126/science.270.5234.286 · Cited by 2,390
Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81118-6 · Cited by 2,150
Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids
Scheinman, R. I., Cogswell, P. C., Lofquist, A. K., & Baldwin, A. S. (1995) · Science · doi:10.1126/science.270.5234.283 · Cited by 1,699
Zhong, H., Voll, R. E., & Ghosh, S. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80066-0 · Cited by 1,210
DNA binding of the glucocorticoid receptor is not essential for survival
Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81183-6 · Cited by 1,068
Ray, A., & Prefontaine, K. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.752 · Cited by 1,064
CREB-binding protein/p300 are transcriptional coactivators of p65
Gerritsen, M. E., Williams, A. J., Neish, A. S., Moore, S., Shi, Y., & Collins, T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.2927 · Cited by 816
Cited by
Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
Yamamoto, Y., & Gaynor, R. B. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11914 · Cited by 1,585
Nuclear Hormone Receptors and Gene Expression
Aranda, A., & Pascual, A. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1269 · Cited by 1,570
The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome
Aird, W. C. (2003) · Blood · doi:10.1182/blood-2002-06-1887 · Cited by 1,131
How stress influences the immune response
Padgett, D. A., & Glaser, R. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00173-x · Cited by 1,059
Series Introduction: The transcription factor NF-κB and human disease
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11891 · Cited by 990
De Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0006 · Cited by 898
“Another way for GR-mediated repression might be the targeting of non-HAT-containing cofactors, bridging p65 or AP-1 activation domains to the RNA polymerase holoenzyme (240, 589) (Fig.”
BackgroundSelf-citationAcetylation of RelA at discrete sites regulates distinct nuclear functions of NF‐κB
Chen, L., Mu, Y., & Greene, W. C. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf660 · Cited by 827
NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis
Roman-Blas, J. A., & Jimenez, S. A. (2006) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2006.04.008 · Cited by 688
Molecular determinants of crosstalk between nuclear receptors and toll-like receptors
Ogawa, S., Lozach, J., Benner, C., Pascual, G., Tangirala, R. K., Westin, S., Hoffmann, A., Subramaniam, S., David, M., Rosenfeld, M. G., et al. (2005) · Cell · doi:10.1016/j.cell.2005.06.029 · Cited by 647
Genomic and nongenomic effects of glucocorticoids
Stahn, C., & Buttgereit, F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0898 · Cited by 594
“This term describes the ability of the glucocorticoid–cGCR complex to inhibit the transactivation function of transcription factors such as activator protein 1 and NFκB by direct or indirect interactions”
BackgroundGlucocorticoid receptor control of transcription: precision and plasticity via allostery
Weikum, E. R., Knuesel, M. T., Ortlund, E. A., & Yamamoto, K. R. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.152 · Cited by 533
Transcription Factor AP1 Potentiates Chromatin Accessibility and Glucocorticoid Receptor Binding
Biddie, S. C., John, S., Sabo, P. J., Thurman, R. E., Johnson, T. A., Schiltz, R. L., Miranda, T. B., Sung, M.-H., Trump, S., Lightman, S. L., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.016 · Cited by 503
NF-κB in inflammation and cancer
Mao, H., Zhao, X., & Sun, S.-C. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01310-w · Cited by 489
Combinatorial roles of nuclear receptors in inflammation and immunity
Glass, C. K., & Ogawa, S. (2006) · Nature Reviews Immunology · doi:10.1038/nri1748 · Cited by 464
One Hormone, Two Actions: Anti- and Pro-Inflammatory Effects of Glucocorticoids
Cruz-Topete, D., & Cidlowski, J. A. (2015) · Neuroimmunomodulation · doi:10.1159/000362724 · Cited by 454
Mechanisms of glucocorticoid receptor signaling during inflammation
Smoak, K. A., & Cidlowski, J. A. (2004) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.06.010 · Cited by 420
Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
Stahn, C., Löwenberg, M., Hommes, D. W., & Buttgereit, F. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.019 · Cited by 419
“Negative regulation by glucocorticoid/glucocorticoid receptor complexes results in reduced transcriptional activities of GCR target genes [19-23], leading to anti-inflammatory and immune-suppressive effects [24].”
BackgroundUpdate on glucocorticoid action and resistance
Nelson, H. S., Leung, D. Y. M., & Bloom, J. W. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.97 · Cited by 413
Stress-Induced Immune Dysregulation: Implications for Wound Healing, Infectious Disease and Cancer
Godbout, J. P., & Glaser, R. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9036-0 · Cited by 386
Glucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of action
Buttgereit, F., Straub, R. H., Wehling, M., & Burmester, G. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20583 · Cited by 367
Penna, G., Amuchastegui, S., Giarratana, N., Daniel, K. C., Vulcano, M., Sozzani, S., & Adorini, L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.145 · Cited by 355
Macrophage migration inhibitory factor
Baugh, J. A., & Bucala, R. (2002) · Critical Care Medicine · doi:10.1097/00003246-200201001-00004 · Cited by 341
Glucocorticoid therapy‐induced skin atrophy
Schoepe, S., Schäcke, H., May, E., & Asadullah, K. (2006) · Experimental Dermatology · doi:10.1111/j.0906-6705.2006.00435.x · Cited by 336
Newton, R., & Holden, N. S. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.038794 · Cited by 328
Mechanisms of glucocorticoid signalling
Schoneveld, O. J. L. M., Gaemers, I. C., & Lamers, W. H. (2004) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2004.09.004 · Cited by 310
Vanden Berghe, W., Vermeulen, L., De Wilde, G., De Bosscher, K., Boone, E., & Haegeman, G. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00412-3 · Cited by 303
Self-citationBeck, I. M. E., Vanden Berghe, W., Vermeulen, L., Yamamoto, K. R., Haegeman, G., & De Bosscher, K. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0013 · Cited by 298
Self-citationThe regulation of muscle mass by endogenous glucocorticoids
Braun, T. P., & Marks, D. L. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00012 · Cited by 273
“Ligand bound GR interferes with the binding of the p65 subunit of NF-κB to the basal transcriptional machinery, preventing it from activating target inflammatory genes (De Bosscher et al., 2000).”
BackgroundCrosstalk between the glucocorticoid receptor and other transcription factors: Molecular aspects
Kassel, O., & Herrlich, P. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.07.003 · Cited by 277
Effects of glucocorticoids on gene transcription
Hayashi, R., Wada, H., Ito, K., & Adcock, I. M. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.011 · Cited by 277
Integrating Interleukin-6 into depression diagnosis and treatment
Hodes, G. E., Ménard, C., & Russo, S. J. (2016) · Neurobiology of Stress · doi:10.1016/j.ynstr.2016.03.003 · Cited by 271
“Through trans-repression, glucocorticoid receptors (GR) can block the ability of NFkB to act as a transcription factor, potentially comprising a method through which stress modulates IL-6 levels (Ray and Prefontaine, 1994; De Bosscher et al., 2000).”
De Bosscher, K. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00297-6 · Cited by 264
A fully dissociated compound of plant origin for inflammatory gene repression
De Bosscher, K., Berghe, W. V., Beck, I. M. E., Van Molle, W., Hennuyer, N., Hapgood, J., Libert, C., Staels, B., Louw, A., & Haegeman, G. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505554102 · Cited by 260
Self-citationBhattacharyya, S., Brown, D. E., Brewer, J. A., Vogt, S. K., & Muglia, L. J. (2007) · Blood · doi:10.1182/blood-2006-10-048215 · Cited by 249
Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids
Almawi, W., & Melemedjian, O. (2002) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0280069 · Cited by 242
PPARs and lipid ligands in inflammation and metabolism
Harmon, G. S., Lam, M. T., & Glass, C. K. (2011) · Chemical Reviews · doi:10.1021/cr2001355 · Cited by 216
Novel glucocorticoid receptor coactivator effector mechanisms
Jenkins, B. D., Pullen, C. B., & Darimont, B. D. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(00)00357-x · Cited by 150
Minireview: glucocorticoids in autoimmunity: unexpected targets and mechanisms
Flammer, J. R., & Rogatsky, I. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-0068 · Cited by 140
Neuroendocrine Regulation of Brain Cytokines After Psychological Stress
Johnson, J. D., Barnard, D. F., Kulp, A. C., & Mehta, D. M. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00053 · Cited by 135
Foxa1 and Foxa2 regulate bile duct development in mice
Li, Z., White, P., Tuteja, G., Rubins, N., Sackett, S., & Kaestner, K. H. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38201 · Cited by 131
MacPherson, A., Dinkel, K., & Sapolsky, R. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.02.021 · Cited by 120
Enhanced Th17 phenotype in individuals with generalized anxiety disorder
Vieira, M. M. M., Ferreira, T. B., Pacheco, P. A. F., Barros, P. O., Almeida, C. R. M., Araújo-Lima, C. F., Silva-Filho, R. G., Hygino, J., Andrade, R. M., Linhares, U. C., et al. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.07.018 · Cited by 118
Optimized glucocorticoid therapy: teaching old drugs new tricks
Strehl, C., & Buttgereit, F. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.026 · Cited by 118
Wieck, A., Grassi-Oliveira, R., do Prado, C. H., Rizzo, L. B., de Oliveira, A. S., Kommers-Molina, J., Viola, T. W., Teixeira, A. L., & Bauer, M. E. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.07.005 · Cited by 63
Implications of glucocorticoid therapy in idiopathic inflammatory myopathies
Hanaoka, B. Y., Peterson, C. A., Horbinski, C., & Crofford, L. J. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.85 · Cited by 57
Nuclear receptor superfamily: Principles of signaling
Germain, P., Altucci, L., Bourguet, W., Rochette-Egly, C., & Gronemeyer, H. (2003) · Pure and Applied Chemistry · doi:10.1351/pac200375111619 · Cited by 53
“Note that as in the case of AP1 [233], squelching of limiting amounts of CBP, which also coactivates NFκB, is unlikely to be involved [240] and GR ligands that dissociate transactivation from transrepression still induce transcriptional interference with NFκB signaling [239].”
Background‘PPAR’ting ways with inflammation
Bailey, S. T., & Ghosh, S. (2005) · Nature Immunology · doi:10.1038/ni1005-966 · Cited by 49
Bladh, L.-G., Lidén, J., Dahlman-Wright, K., Reimers, M., Nilsson, S., & Okret, S. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.005801 · Cited by 49
“This is consistent with evidence that the GR inhibits NF- B and AP-1 independently of the levels of common coactivators such as cAMP response element binding protein binding protein (De Bosscher et al., 2000; De Bosscher et al., 2001).”
Dopamine up-regulates Th17 phenotype from individuals with generalized anxiety disorder
Ferreira, T. B., Kasahara, T. M., Barros, P. O., Vieira, M. M. M., Bittencourt, V. C. B., Hygino, J., Andrade, R. M., Linhares, U. C., Andrade, A. F., & Bento, C. A. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.06.009 · Cited by 40
Taniguchi, Y., Iwasaki, Y., Tsugita, M., Nishiyama, M., Taguchi, T., Okazaki, M., Nakayama, S., Kambayashi, M., Hashimoto, K., & Terada, Y. (2010) · Endocrinology · doi:10.1210/en.2009-1254 · Cited by 36
Molecular Pathogenesis of Multiple Myeloma
Maura, F., & Bergsagel, P. L. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.010 · Cited by 19
Metadata
- Authors
- De Bosscher, K., Vanden Berghe, W., Vermeulen, L., Plaisance, S., Boone, E., & Haegeman, G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-04-11
- Volume
- 97
- Issue
- 8
- Pages
- 3919-3924
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2147277158
- Cited by
- 335
- References
- 42
- FWCI
- 10.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.